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Objectives: Evidence based medicine has been used for about two decades as 
methodology for obtaining, evaluating and presenting information on health 
related topics. The present study investigated the question of the appearance 
of the ideas of evidence based medicine in documents describing the function-
ing of European health care systems. MethOds: The documents available in the 
European Observatory on Health Systems and Policies database were considered 
to reliable represent the health system of European countries. Structured text 
analysis was carried out according to previously described methodology. All evalu-
ation steps were carried out in parallel by two researchers (K.M. and Sz.L.). Two 
studies carried our previously on related topics were used to relate the results 
obtained in the present study with data of the literature. Results: The cumula-
tive length of the documents was 6449 pages; there was no document without 
mentioning the idea of evidence based medicine. Among the altogether 413 men-
tioning of evidence based medicine, we were able to categorise 208 representa-
tions of the idea into one of the following 4 topics: 1. resources of health care, 2. 
health technology assessment, 3. organisation of health care and 4. environment 
of health care within the society. Evidence based medicine was mentioned 57 
in connection with the resources of health care, whereas 31 mentioning were 
related to health technology assessment. Organisation of health care was men-
tioned together with evidence based medicine at 56 occasions, whereas the idea 
of evidence based medicine was related to the social environment of health care 
in 64 instances. cOnclusiOns: The results of the present data collection indicate 
that the methodology of evidence based medicine has already been widely used 
within the documents describing health systems and policies in Europe. However, 
there were considerably differences in the extent and depth of applying evidence 
based medicine methodology.
PHP73
PHarmacoeconomics and its aPPlications – emerging role in india
Janodia M.1, Patel A.2, Udupa N.1
1Manipal University, Manipal, India, 2Medical Marketing and Economics LLC, Oxford, MS, USA
Objectives: Pharmacoeconomics is the application of economics to assess 
pharmaceutical and health care products that helps evaluate economic, clinical 
and humanistic outcomes of health care products and interventions. It gives 
health care decision makers, providers and patients with valuable informa-
tion for optimal use and allocation of limited health care resources. In India, 
the awareness of pharmacoeconomics is relatively low among policy makers, 
academia and industry. As India’s pharmaceutical market changes and evolves, 
the study of pharmacoeconomics and associated research is expected to gain 
momentum. MethOds: Secondary research was conducted using PubMed. 
Several search terms like “pharmacoeconomics”, “cost minimization”, “cost 
benefit”, “cost utility”, and “cost effectiveness” analysis were used. These terms 
were also used in different combinations, e.g., “Cost Minimization Analysis and 
Pharmacoeconomics and India”, “Cost Benefit Analysis and Pharmacoeconomics 
and India”, to extract relevant studies. No search term or time restrictions 
were applied while extracting studies. Results: Overall, a total of 228 stud-
ies were extracted using the search terms. “Pharmacoeconomics and India” 
yielded 192 results out of which only five studies were relevant to pharmaco-
economics in India. Search terms “Cost Minimization Analysis and India and 
Pharmacoeconomics” gave only two results. Fifteen results were obtained for 
the term “Cost Benefit Analysis and Pharmacoeconomics and India” out of 
which four studies were relevant to the objective. “Cost Utility Analysis and 
Pharmacoeconomics and India” resulted in four results out of which two were 
repetitions of results from “cost minimization analysis”. “Cost effectiveness 
analysis and pharmacoeconomics and India” resulted in 15 results; 10 in last 
10 years and only 2 were relevant. cOnclusiOns: As seen from the results, not 
much pharmacoeconomic research has been conducted in India suggesing the 
dearth of literature in this area in India. As the Indian pharmaceutical market 
evolves and policies change, greater amount and rigorous pharmacoeconomics 
research may be needed.
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Objectives: To explore the attitudes and perceptions of patient safety culture for 
health care workers in China by using a modified Hospital Survey on Patient Safety 
Culture (HSPSC) questionnaire. MethOds: The survey measuring 10 dimensions 
of patient safety culture with 36 items was conducted from 32 hospitals in 15 cit-
ies all across China. We computed descriptive statistics and Chi-Square test was 
performed to explore the differences on the perception of patient safety culture 
in groups of different work units, positions and qualification levels. SPSS 17.0 was 
used to perform data extraction and analysis. Results: A total of 1500 question-
naires were distributed of which 1160 were responded validly (response rate 77%). 
Seven hundred and twenty two (66%) of the respondents were nurses, 386 (33%) 
were surgical clinicians and 343 (30%) were internal medicine clinicians. The posi-
tive response rate for the 10 patient safety culture dimensions ranged from 45% 
to 88%, the mean positive response rate was 65%. The lowest positive response 
rate of dimension was “Staffing” (45%), while the highest positive response rate of 
dimension was “Organization Learning-Continuous Improvement” (88%). The positive 
response rate of two dimensions of nurse was lower than that of physicians (“Overall 
Perceptions of Patient Safety” and “Communication Openness” P < 0.05). Furthermore, the 
positive response rate of physicians with high qualification (chief physicians) on 
two dimensions (“Overall Perception of Patient safety” and “Feedback & Communication 
About Errors” P < 0.05) was higher than those having a low qualification level (resi-
dents). cOnclusiOns: The results show that amongst the health care workers 
surveyed in China there was a positive attitude towards the patient safety culture 
within their organizations.
this study was to assess the trends which drive risk sharing agreements with the 
Pharmaceutical Benefits Advisory Committee (PBAC) within a four month period in 
2013. MethOds: All PBAC decisions from August to November 2013 were surveyed 
by looking at the general RSA structures outlined in the PBAC guidelines. The fol-
lowing data were extracted from each appraisal: assessment outcome (positive or 
negative), RSA consensus (yes or no), RSA type (rebate and recovery, price volume, 
data provision, shared deeds), therapeutic area, product price, product incremen-
tal cost-effectiveness ratio, market size, structure of trial, trial outcomes, and the 
availability of alternative therapies. Results: The analysis revealed that 44% of 
PBAC decisions incorporated some form of an RSA, and 91% of products with RSAs 
received a positive PBAC decision. The majority of RSAs were rebate recovery or price 
volume arrangements, where the PBAC was concerned with the product’s use in a 
larger-than-specified population. cOnclusiOns: The results of this study indicate 
the PBAC readily enters into RSAs when doubt exists surrounding the potential cost 
or efficacy of a drug. Accurately identifying areas of product risk and proposing an 
RSA to address it can lead to a favourable decision from the PBAC.
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Objectives: The objective of this study was to compare the Health Technology 
Assessment (HTA) timing and decisions for recently launched products in South 
Korea and Taiwan, and to provide insight into launch strategies in these mar-
kets. MethOds: We analysed all products that were assessed for reimbursement 
by the Health Insurance Review & Assessment Service (HIRA) in Korea and by 
the National Health Insurance Administration (NHIA) and the Centre for Drug 
Evaluation (CDE) in Taiwan from January 2012 to March 2014. Where relevant, the 
details of the assessments have been extracted from the NHIA meeting minutes, 
CDE reports and HIRA reports. Results: Since January 2012, 17 products were 
assessed by the reimbursement authorities in both Korea and Taiwan. 12 products 
received the same reimbursement decisions from both countries, while five prod-
ucts had divergent results. Of 12 products that received the same decisions, seven 
products were first assessed and reimbursed by Korea and then also reimbursed 
in Taiwan later, while only three products were first assessed and reimbursed by 
Taiwan and later followed by Korea. The other two products were assessed at the 
same time in both countries. Of five products that received different reimburse-
ment decisions, two products were first assessed by Korea and Taiwan respectively, 
while the other product was assessed at the same time in both countries. Though 
the sample size is limited, these data suggest a possible positive influence of 
Korean HTA decisions on those in Taiwan. The average time difference between 
the Korea and Taiwan HTA assessments was 7.7 months, while Taiwan HTA assess-
ments, on average, lagged behind Korea by 2.6 months. cOnclusiOns: In general, 
Taiwan HTA assessments lag behind Korea by 2-3 months. This may result from a 
proactive launching strategy from manufactures, as HTA decisions made in Korea 
may have a positive influence on those in Taiwan.
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Objectives: More and more papers about pharmacoeconomics and outcome 
research were published in China. The aim of this study was to evaluate the quality 
of Chinese pharmacoeconomics study and outcome research through analyze 
papers published in the peer-reviewed literature in Chinese over the last five 
years. MethOds: We conducted full-text paper searches in public databases from 
2009 to 2013 in China. A search strategy and inclusion criteria were set up to iden-
tify the articles to be included. The search identified 820 studies, of which 411 were 
included. Then papers were evaluated through a framework which was based on 
Pharmacoeconomics guideline. Results: Our results showed that a large number 
of published studies were of suboptimal quality. Most of pharmaceonomics and 
outcome research were conduct by doctors (33.6%) and pharmacists (54%) in China. 
Prospective studies (65.9%) were the most common study design, while most data 
were derived from the clinical trials; Only 8% of them included articles clearly 
stated the study perspective; More than half studies (56.2%) only computed drug 
expenditure in cost estimation; 2.2% of articles conducted discounting; 63.5% of 
studies performed the incremental analysis, however, most studies presented 
the cost-effectiveness ratios as incremental cost-effectiveness ratio; Sensitive 
analysis were reported by 71.3% of the included studies, nonetheless, the choice 
of variables for sensitivity analysis wasn’t justified; A few studies (7.3%) presented 
the transferability of the results. cOnclusiOns: The above data signify that the 
quality of pharmacoeconomic evaluations needs improvement. There were just 
few studies which had well-designed schemes, high-qualified data and suitable 
methodology, partly owing to the doctors and pharmacists’ lack of pharmaceo-
nomics expertise and knowledge. It implied China should improve the training 
of pharmaceonomics and outcome research training in doctors and pharmacists. 
Moreover, a further study of the new technology on pharmacoeconomy should 
not be neglected.
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